Patents by Inventor Norman E. Sharpless

Norman E. Sharpless has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9808461
    Abstract: The presently disclosed subject matter relates to methods and compositions for protecting cells and or tissues from damage due to ischemia. In particular, the presently disclosed subject matter relates to the protective action of cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to, or that are at risk of, ischemia.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: November 7, 2017
    Assignees: The University of North Carolina at Chapel Hill, G1 Therapeutics, Brigham and Women's Hospital
    Inventors: Derek P. DiRocco, Norman E. Sharpless, Jay C. Strum, John E. Bisi, Patrick J. Roberts, Benjamin D. Humphreys, Kwok-Kin Wong
  • Patent number: 9616062
    Abstract: The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or that are at risk of exposure to DNA damage.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: April 11, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Norman E. Sharpless, Patrick J. Roberts, Kwok-Kin Wong, Soren Johnson
  • Publication number: 20140275067
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: G1 Therapeutics, Inc.
    Inventors: Norman E. Sharpless, Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Publication number: 20140271460
    Abstract: This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: G1 THERAPEUTICS, INC.
    Inventors: Norman E. Sharpless, Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Publication number: 20140271466
    Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: G1 THERAPEUTICS, INC.
    Inventors: Norman E. Sharpless, Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Publication number: 20140275066
    Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: G1 THERAPEUTICS, INC.
    Inventors: Norman E. Sharpless, Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Publication number: 20140274896
    Abstract: This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: G1 THERAPEUTICS, INC.
    Inventors: Norman E. Sharpless, Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
  • Publication number: 20140227222
    Abstract: The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or that are at risk of exposure to DNA damage.
    Type: Application
    Filed: December 11, 2013
    Publication date: August 14, 2014
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Norman E. Sharpless, Patrick J. Roberts, Kwok Wong, Yan Liu, Soren Johnson
  • Publication number: 20120100100
    Abstract: The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or that are at risk of exposure to DNA damage.
    Type: Application
    Filed: May 13, 2010
    Publication date: April 26, 2012
    Inventors: Norman E. Sharpless, Patrick J. Roberts, Kwok Wong, Yan Liu, Soren Johnson
  • Patent number: 8158347
    Abstract: The presently disclosed subject matter provides methods for determining the molecular age of a tissue. Also provided are methods for employing a molecular age that has been determined for a tissue for assessing the appropriateness of various therapeutic applications for the tissue or a subject comprising the tissue.
    Type: Grant
    Filed: September 27, 2005
    Date of Patent: April 17, 2012
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Norman E. Sharpless, Krishnamurthy Janakiraman
  • Publication number: 20110224221
    Abstract: Methods for reducing or preventing the effects of ionizing radiation in healthy cells arc provided. The methods relate to the use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors to induce transient quiescence in CDK4/6 dependent cells, such as hematopoietic stem cells and/or hematopoietic progenitor cells. Radioprotection can be effected in mammals by treatment with selective CDK4/6 inhibitor compounds either before, at the same time as, or after exposure to the ionizing radiation.
    Type: Application
    Filed: October 1, 2009
    Publication date: September 15, 2011
    Inventors: Norman E. Sharpless, Chad D. Torrice, Matthew R. Ramsey, Soren Johnson, Jessica F. Bell
  • Publication number: 20110224227
    Abstract: Methods for reducing or preventing the effects of cytotoxic compounds in healthy cells are provided. The methods relate to the use of selective cyclin-dependent kinase (CDK) 4/6 inhibitors to induce transient quiescence in CDK4/6 dependent cells, such as hematopoietic stem cells and/or hematopoietic progenitor cells. Also described is a method of selecting compounds for reducing or preventing the effects of cytotoxic agents compounds in healthy cells.
    Type: Application
    Filed: October 1, 2009
    Publication date: September 15, 2011
    Inventors: Norman E. Sharpless, Jay C. Strum, John E. Bisi, Patrick J. Roberts, Matthew R. Ramsey
  • Publication number: 20090220465
    Abstract: Methods are described for promoting or maintaining self-renewal of a stem cell expressing or expected to express p16INK4a employing p16INK4a inhibitors. Methods are also described for increasing the amount of self-renewing stem cells in a non-infant subject, as well as for enhancing engraftment of a stem cell expressing p16INK4a. Additionally, methods are described for identifying p16INK4a inhibitors.
    Type: Application
    Filed: November 7, 2006
    Publication date: September 3, 2009
    Applicants: THE GENERAL HOSPITAL CORPORATION, UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
    Inventors: David T. Scadden, Viktor Janzen, Randolf Forkert, Norman E. Sharpless
  • Publication number: 20080108062
    Abstract: The presently disclosed subject matter provides methods for determining the molecular age of a tissue. Also provided are methods for employing a molecular age that has been determined for a tissue for assessing the appropriateness of various therapeutic applications for the tissue or a subject comprising the tissue.
    Type: Application
    Filed: September 27, 2005
    Publication date: May 8, 2008
    Inventors: Norman E. Sharpless, Krishnamurthy Janakiraman